Theme news

SHERIDAN, WYOMING – July 29, 2025 – In a landscape defined by evolving dental materials, Dentsply Sirona’s AH Plus® continues to set the standard in endodontic sealing—celebrating 30 years of clinical trust, scientific validation, and global use across more than 800 million root canal procedures.

Three Decades of Clinical Consistency and Scientific Validation

Originally launched in Europe in 1995, AH Plus® has become the most extensively researched endodontic sealer on the market. To mark its 30th anniversary, Dentsply Sirona has published a comprehensive scientific manual showcasing peer-reviewed studies that confirm its efficacy across diverse obturation techniques and clinical scenarios. Spanning data from over 3,400 patients and nearly 3,800 teeth, the manual strengthens the product’s legacy as a benchmark material in endodontics.

Workflow Reliability Through Proven Chemistry

SHERIDAN, WYOMING – July 29, 2025 – Dentsply Sirona has appointed veteran medtech executive Daniel Scavilla as President and Chief Executive Officer, effective August 1, 2025, in a leadership move designed to accelerate its ongoing transformation, deepen innovation, and unlock new commercial opportunities across the global dental market.

A leadership shift with proven operational impact

Scavilla joins the executive ranks from within Dentsply Sirona’s Board of Directors, where he has served since February 2025. His appointment follows the planned departure of outgoing CEO Simon Campion, who concludes his three-year tenure on July 31. With over 30 years of experience spanning Johnson & Johnson and Globus Medical, Scavilla brings a track record of leading major integrations, scaling commercial infrastructure, and advancing market leadership positions.

SHERIDAN, WYOMING – July 29, 2025 – Dentsply Sirona is doubling down on its commitment to delivering more than just clinical education at DS World Las Vegas 2025 by unveiling a headline entertainment and speaker roster that blends celebrity impact with entrepreneurial insight. Taking place September 25–27 at the MGM Grand, this flagship event will feature Emmy-winning comedian Dana Carvey, Grammy-winning musician Sheryl Crow, and OrangeTheory co-founder Ellen Latham in a format designed to inspire, entertain, and empower the global dental community.

Entertainment that Builds Connection and Culture

SHERIDAN, WYOMING – July 29, 2025 – Dentsply Sirona is redefining digital chairside workflows with the next evolution of its iconic CEREC system, now seamlessly integrated into the DS Core cloud platform. Celebrating four decades of continuous innovation, the CEREC system combines precision dentistry with real-time digital collaboration—enabling practices to deliver same-day restorations faster, more efficiently, and with greater patient engagement than ever before.

A 40-Year Legacy Meets Modern Cloud Dentistry

Launched in 1985, CEREC (Chairside Economical Restoration of Esthetic Ceramics) pioneered single-visit restorations. Today, its integration with DS Core marks a significant milestone in connected dentistry. This cloud-based platform centralizes intraoral scans, design data, material selection, and production control—allowing clinicians to move seamlessly from scanning to milling with remote access and streamlined workflows.

SHERIDAN, WYOMING – July 29, 2025 – Bio-Rad Laboratories has named Rajat Mehta as its new Executive Vice President of Global Commercial Operations, signaling a strategic push to accelerate growth across its diagnostics and life sciences business lines. Mehta, whose appointment takes effect August 4, 2025, brings broad cross-sector expertise and a proven track record of commercial execution in the biopharma and scientific instrumentation industries.

New commercial leadership aimed at scaling global market impact

With over two decades of experience spanning Labcorp, Thermo Fisher Scientific, and Dow Chemical, Mehta is positioned to enhance Bio-Rad’s commercial alignment across geographies and market verticals. His appointment follows the planned retirement of industry veteran Mike Crowley, who has served in senior roles at Bio-Rad since 1998 and helped shape its global sales infrastructure over the past decade.

SHERIDAN, WYOMING – July 29, 2025 – In a swift regulatory reversal, the U.S. Food and Drug Administration (FDA) has lifted its recommendation for a voluntary hold on Sarepta Therapeutics’ gene therapy Elevidys for ambulatory Duchenne muscular dystrophy (DMD) patients—restoring immediate commercial viability for the treatment and stabilizing investor confidence after weeks of uncertainty.

FDA Reinstates Ambulatory Access Following Brief Hold

The FDA’s updated position, delivered barely one business day after launching a formal investigation into the death of an 8-year-old Brazilian patient, clears Sarepta to resume distribution of Elevidys to ambulatory patients in the United States. The agency stated that the death was likely due to an acute influenza A infection compounded by immunosuppression—not the therapy itself.

SHERIDAN, WYOMING – July 29, 2025 – Roche has unveiled compelling early-stage data for its next-generation Alzheimer’s therapy, trontinemab, which demonstrated rapid and deep amyloid plaque clearance in patients after just seven months of treatment. The findings, presented at the 2025 Alzheimer’s Association International Conference in Toronto, suggest a potential leap beyond first-generation FDA-approved antibodies and set the stage for a new class of blood-brain barrier-penetrating biologics.

Trontinemab achieves over 90% amyloid clearance in seven months

In the Phase Ib/IIa Brainshuttle AD trial, 91% of participants receiving the highest dose of trontinemab (3.6 mg/kg) became amyloid-negative on PET scans within seven months. Notably, 72% achieved "deep clearance" on standardized plaque rating scales—a level of response that typically requires over 18 months with currently approved therapies.

SHERIDAN, WYOMING – July 29, 2025 – Boehringer Ingelheim has entered a strategic collaboration with Re-Vana Therapeutics, aiming to co-develop long-acting injectable therapies for serious eye diseases using Re-Vana’s proprietary sustained-release delivery platform. The multi-target agreement could exceed $1 billion in total value and marks a significant move by Boehringer into the ophthalmology space.

Pioneering extended-release drug delivery for ophthalmology

The deal centers around Re-Vana’s injectable polymer-based system, designed to deliver drugs to the eye over six to twelve months with a single administration. This innovation could dramatically reduce treatment burdens for patients with chronic retinal diseases, who currently require frequent intraocular injections.

SHERIDAN, WYOMING – July 29, 2025 – GSK has launched one of the largest licensing collaborations of the year, partnering with China-based Hengrui Pharma in a deal that could reach up to $12 billion. The multi-program alliance aims to accelerate global development of 12 investigational therapies targeting oncology, respiratory diseases, and immunology — marking a major step in GSK’s bid to diversify and deepen its late-stage pipeline.

A strategic cornerstone: HRS-9821 for COPD

At the center of the collaboration is Hengrui’s investigational COPD treatment HRS-9821, a dual PDE3/4 inhibitor now in Phase I development. The candidate is being explored as an add-on maintenance therapy and may be delivered via dry-powder inhaler — a formulation that aligns well with GSK’s robust respiratory franchise, which includes industry mainstays like Advair and Nucala.

SHERIDAN, WYOMING – July 29, 2025 – The American Medical Association (AMA) has issued a public plea urging Health Secretary Robert F. Kennedy Jr. to preserve the U.S. Preventive Services Task Force (USPSTF), following reports that the panel could be dissolved due to ideological concerns. The potential shakeup, while not yet finalized, has sparked widespread concern across the healthcare community and could significantly impact access to preventive care services nationwide.

Potential dissolution raises alarms over clinical and insurance ripple effects

SHERIDAN, WYOMING – July 29, 2025 – Sarepta Therapeutics is once again under regulatory spotlight following the death of an 8-year-old boy in Brazil who had received its gene therapy Elevidys, triggering an FDA investigation and fresh market turbulence for the embattled biotech.

While Brazilian authorities and partner company Roche have attributed the fatality to severe influenza A infection compounded by immunosuppression, the FDA has launched a formal probe. The death, though deemed “unrelated to treatment with Elevidys” by the reporting physician, adds to growing concerns around the safety profile of Sarepta’s adeno-associated virus (AAV)-based gene therapy platform.

Regulators Reassess Risk Amid Fatality and Flu Season Timing

SHERIDAN, WYOMING – July 29, 2025 – As the Alzheimer’s treatment market evolves beyond anti-amyloid antibodies, leading biopharma companies are doubling down on symptomatic therapies to address the daily struggles of patients and caregivers. While breakthrough drugs like Leqembi and Kisunla have changed the landscape with disease-modifying potential, their limitations are propelling renewed interest in managing Alzheimer’s-related psychosis, agitation, and cognitive decline—particularly in mid-to-late-stage patients.

Repositioning Symptom Relief as an Industry Priority

SHERIDAN, WYOMING – July 29, 2025 – As the Alzheimer’s treatment landscape evolves beyond legacy amyloid-targeting approaches, five upcoming trial readouts are expected to deliver pivotal data that could shift both clinical practice and market leadership. From repurposed GLP-1 drugs to precision antibody therapies, leading pharma and biotech players are advancing differentiated strategies to address persistent unmet needs in Alzheimer’s care.

Data Milestones Poised to Shape the Post-Amyloid Era

While Biogen and Eisai’s Leqembi recently became the first Alzheimer’s drug to secure full FDA approval, lingering questions around efficacy, safety, and accessibility continue to drive innovation in the space. The next wave of readouts promises to introduce more convenient delivery formats and explore entirely new biological targets, including:

SHERIDAN, WYOMING – July 29, 2025 – As Q2 earnings season ramps up, a diverse group of biotech leaders—ranging from Sarepta Therapeutics to Vertex Pharmaceuticals—find themselves navigating vastly different strategic terrain. From regulatory setbacks and gene therapy scrutiny to CRISPR approvals and pain therapy innovation, this quarter’s results could redefine investor confidence and reshape R&D roadmaps across the sector.

Sarepta Confronts Regulatory Turbulence and Gene Therapy Fallout

SHERIDAN, WYOMING – July 25, 2025 – Philips has secured FDA 510(k) clearance for its next-generation UroNav platform, reinforcing the company’s leadership in image-guided interventions for prostate cancer. The upgraded UroNav 2.0 system is designed to unify MR/ultrasound fusion imaging with advanced workflow integration, helping clinicians deliver more accurate, less invasive, and highly personalized focal therapies.

MR/Ultrasound Fusion Powers Real-Time Targeting

At the heart of UroNav 2.0 is its fusion of pre-acquired MRI with live ultrasound data. This real-time hybrid imaging enables clinicians to precisely locate lesions and navigate biopsies and ablations with improved spatial accuracy. The platform supports better targeting, particularly in high-risk prostate cancer cases.

SHERIDAN, WYOMING – July 25, 2025 – Philips and Radboud university medical center (Radboudumc) are conducting one of the first large-scale studies to explore the impact of prolonged physical activity on atrial fibrillation, leveraging wearable monitoring technology during the 4Days Marches in the Netherlands. The collaboration combines clinical expertise with cutting-edge sensor technology to better understand how exercise influences this widespread heart rhythm disorder.

Continuous Monitoring for Deeper Insight into Atrial Fibrillation

SHERIDAN, WYOMING – July 25, 2025 – Philips Foundation has announced the results of its 2024 activities in a newly published Annual Report, celebrating a milestone year that brought quality healthcare access to 46.5 million people globally—up from 28 million in 2023. The results mark a significant stride toward the Foundation’s 2030 goal of reaching 100 million underserved individuals each year.

Strategic Projects and Investments Drive Expansion

Throughout 2024, the Foundation initiated 22 new healthcare projects and five early-stage impact investments, with a strategic focus on primary care in underserved regions, particularly in India and Latin America. These initiatives leveraged Philips' health technology expertise to address rising non-communicable disease burdens and maternal health challenges.

SHERIDAN, WYOMING – July 25, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA) has confirmed the exchange ratio for its 2024 dividend, announcing a share-based conversion rate of one new common share for every 23.6353 existing shares. The ratio was determined based on the volume-weighted average price of Philips shares traded on Euronext Amsterdam across May 30, June 2, and June 3, 2025, which stood at EUR 20.0600.

The final exchange ratio ensures that the gross value of the dividend in shares equates to approximately EUR 0.85, aligning with the company’s stated dividend target. As a result of this share-based payout, Philips will issue 22,980,748 new common shares.

Strategic Shareholder Participation and Dividend Structure

SHERIDAN, WYOMING – July 25, 2025 – Royal Philips has initiated a major international clinical trial to evaluate its new ultra-low X-ray dose technology designed for coronary procedures. The RADIQAL trial aims to generate real-world evidence that the innovation can significantly reduce radiation exposure for both patients and clinical staff without compromising the image quality or procedural performance critical to interventional cardiology.

Strategic push for radiation dose reduction in cardiology

As a global leader in health technology, Philips is targeting one of the central challenges in image-guided therapy: how to lower radiation exposure during procedures like percutaneous coronary intervention (PCI) while maintaining diagnostic confidence and procedural safety.

SHERIDAN, WYOMING – July 25, 2025 – In a significant move reshaping national vaccine policy, the U.S. Department of Health and Human Services (HHS) has announced it will eliminate thimerosal from all influenza vaccines distributed in the United States. The decision follows a unanimous vote by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) on June 26, 2025, and marks the end of an era for a preservative that has been both a practical necessity and a source of public debate for over two decades.

Strategic impact on manufacturers and supply chain

While thimerosal is currently used in only about 4% of flu vaccines—mainly multi-dose vials—the HHS ruling will require vaccine manufacturers to fully transition to thimerosal-free production. This includes replacing the final few thimerosal-containing products, namely two from Seqirus and one from Sanofi Pasteur, according to CDC data.